Stephen Bradley, MD
General Practice · Waianae, HINPI 1295825651
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,334 of the $56,527 with a category attached, or 94.4%. Novo Nordisk accounts for 99.8% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $37,801, more than ten times the $13 reported in 2019. Among general practice clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $1615.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$56K
- Philips North America LLC$48
- GSK$47
- Amgen$13
What the payments were for
- Speaking & faculty fees$53,33494%
- Travel & lodging$2,1244%
- Food & beverage$1,0692%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $56,419 |
| Philips North America LLC | 1 | $48 |
| GSK | 2 | $47 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$56,214
How this compares
$56,527 in reported general payments places this provider in the 95th percentile of 650 general practice providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 28 | $47,332 |
| EliquisApixaban | 25 | $31,228 |
| OzempicSemaglutide | 13 | $16,727 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $13,779 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,310 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,723 |
| Atorvastatin Calcium | 141 | $1,537 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 12 | $1,298 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $878 |
| Losartan Potassium | 78 | $727 |
| Ventolin HfaAlbuterol Sulfate | 14 | $694 |
| Fluticasone Propionate | 27 | $691 |
| Ibuprofen | 34 | $530 |
| Valsartan | 14 | $477 |
| Allopurinol | 32 | $452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $56,419 | $16,72713 claims |
| GSKIncruse Ellipta | $47 | $4,31012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 650 general practice providers in Hawaii.
Other general practice in Waianae
- Terrence CodingtonKailua Kona$1.2M
- Philip SuhHonolulu$299K
- Daniel MayedaKahului$190K
- Kent HironakaHonolulu$94K
- Jason AkoHonolulu$81K
- Wynn OkudaHonolulu$60K
- Russell TacataHonolulu$22K
- Eugene AzumaHonolulu$14K
- Jeffrey SonsonKailua$11K
- Blake KitamuraHonolulu$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.